FUTURE ONCOLOGY Journal
Overview
publication venue for
- Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review 2025
- Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies 2024
- A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer 2024
- Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer. 18:2979-2986. 2022
- Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 Phase III study design. 18:425-436. 2022
- Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. 15:2073-2082. 2019
- Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET. 14:527-536. 2018
- Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. 12:2689-2699. 2016
Identity
International Standard Serial Number (ISSN)
- 1479-6694
Electronic International Standard Serial Number (EISSN)
- 1744-8301
Other
journal abbreviation
- FUTURE ONCOL